Safe Orthopaedics reported 3Q19 orthopedic revenue of EUR 1.2MM (USD $1.3MM), +40.8% vs. 3Q18.
- Adoption of the SteriSpine PS pedicle screw and SteriSpine VA vertebral augmentation balloon contributed to growth, as did continued training of newly recruited sales representatives
- Direct sales in France, Germany and the U.K. decreased by -7% in the quarter, while indirect sales via distributors increased 124%
- In late September 2019, the company announced recruitment of a new VP of Strategy and Marketing as well as a Director of Sales for the French and U.K. markets to reinvigorate the direct salesforce
ORTHOWORLD estimates segment sales and growth on an as-reported basis, as follows ($MM).
3Q19 | 3Q18 | $ Chg | % Chg | |
---|---|---|---|---|
Spine | $1.3 | $0.9 | $0.4 | 40.8% |
9mo 19 | 9Mo 18 | $ Chg | % Chg | |
---|---|---|---|---|
Spine | $3.6 | $2.8 | $0.8 | 29.6% |
Mike Evers is ORTHOWORLD’s Market Analyst. He can be reached by email.
Safe Orthopaedics reported 3Q19 orthopedic revenue of EUR 1.2MM (USD $1.3MM), +40.8% vs. 3Q18.
Adoption of the SteriSpine PS pedicle screw and SteriSpine VA vertebral augmentation balloon contributed to growth, as did continued training of newly recruited sales representatives
Direct sales in France, Germany and the U.K. decreased by...
Safe Orthopaedics reported 3Q19 orthopedic revenue of EUR 1.2MM (USD $1.3MM), +40.8% vs. 3Q18.
- Adoption of the SteriSpine PS pedicle screw and SteriSpine VA vertebral augmentation balloon contributed to growth, as did continued training of newly recruited sales representatives
- Direct sales in France, Germany and the U.K. decreased by -7% in the quarter, while indirect sales via distributors increased 124%
- In late September 2019, the company announced recruitment of a new VP of Strategy and Marketing as well as a Director of Sales for the French and U.K. markets to reinvigorate the direct salesforce
ORTHOWORLD estimates segment sales and growth on an as-reported basis, as follows ($MM).
3Q19 | 3Q18 | $ Chg | % Chg | |
---|---|---|---|---|
Spine | $1.3 | $0.9 | $0.4 | 40.8% |
9mo 19 | 9Mo 18 | $ Chg | % Chg | |
---|---|---|---|---|
Spine | $3.6 | $2.8 | $0.8 | 29.6% |
Mike Evers is ORTHOWORLD’s Market Analyst. He can be reached by email.
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
ME
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.